Amy Reeves, MD
Family Medicine · Hot Springs, ARNPI 1831103050
Payments from drug & device makers
Across 275 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$790
- Pfizer$461
- AstraZeneca$427
- Lilly USA, LLC$274
- Otsuka America Pharmaceutical, Inc.$178
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,89799%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,185 |
| GSK | 48 | $790 |
| Pfizer | 23 | $461 |
| AstraZeneca | 13 | $427 |
| Lilly USA, LLC | 19 | $274 |
| Otsuka America Pharmaceutical, Inc. | 8 | $178 |
| Amgen(2 entities) | 11 | $174 |
| Novo Nordisk | 11 | $171 |
| Procept Biorobotics Corporation | 1 | $156 |
| Inari Medical, Inc. | 1 | $156 |
| Sumitomo Pharma America, Inc. | 7 | $122 |
| Exact Sciences | 5 | $80 |
| Sunovion Pharmaceuticals Inc. | 10 | $78 |
| Astellas Pharma US Inc | 4 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Abbott | 4 | $63 |
| Lundbeck LLC | 3 | $50 |
| Shield Therapeutics Inc | 3 | $47 |
| Eisai Inc. | 3 | $41 |
| Boehringer Ingelheim | 2 | $34 |
| Dexcom, Inc. | 2 | $33 |
| Merck | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Edwards Lifesciences | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Alk-abello, Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Inogen, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$156
- FLOWTRIEVER CATHETER, S$156
- CT THROMBECTOMY SYSTEM KIT$156
- FARXIGA$125
- NURTEC ODT$125
- BREZTRI$121
- AREXVY$121
- REXULTI$121
- QULIPTA$109
- UBRELVY$109
How this compares
$4,927 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $149,189 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $75,894 |
| JardianceEmpagliflozin | 47 | $45,689 |
| FarxigaDapagliflozin Propanediol | 60 | $45,607 |
| EliquisApixaban | 63 | $40,507 |
| TrulicityDulaglutide | 26 | $38,155 |
| JanuviaSitagliptin Phosphate | 25 | $34,367 |
| MounjaroTirzepatide | 21 | $22,421 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $21,283 |
| GemtesaVibegron | 20 | $20,666 |
| EntrestoSacubitril/Valsartan | 29 | $19,990 |
| RybelsusSemaglutide | 12 | $11,163 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $10,092 |
| MyrbetriqMirabegron | 14 | $8,999 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $7,410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $171 | $160,352125 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $790 | $82,824112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $427 | $66,89085 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $274 | $60,57647 claims |
| Boehringer IngelheimJardiance | $34 | $45,68947 claims |
| MerckJanuvia, Janumet | $31 | $44,45936 claims |
| PfizerEliquis | $461 | $40,50763 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $122 | $20,66620 claims |
| Astellas Pharma US IncMyrbetriq | $72 | $8,99914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Hot Springs
- Jodi SansonHot Springs$1.7M
- Kevin HaleHot Springs$37K
- Anna ParchmanHot Springs$28K
- Hunter CarringtonHot Springs$21K
- Scott AndersonHot Springs$15K
- Robert ParrottHot Springs$15K
- John ErwinHot Springs$12K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.